GURU.Markets stock price, segment price, and overall market index valuation
The company's share price NovoCure Limited
NovoCure is a company that has developed a unique technology for treating cancer using electrical fields (Tumor Treating Fields). Its stock price reflects both its success in treating brain cancer and the hopes for applying this technology to other tumor types, which is the subject of ongoing research.
Share prices of companies in the market segment - Miscellaneous oncology
NovoCure is a company that has developed a unique technology for treating cancer using electrical fields (Tumor Treating Fields), which is its sole segment. We classify it as part of the Miscellaneous Oncology sector, and the chart below reflects the dynamics of the entire alternative cancer treatment industry.
Broad Market Index - GURU.Markets
NovoCure is an oncology company that has developed an innovative cancer treatment called Tumor Treatment Fields (TTFields), which uses electrical fields. It is a component of the GURU.Markets index. The chart below represents the market. See how NovoCure shares compare to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
NVCR - Daily change in the company's share price NovoCure Limited
NovoCure, an oncology company, has volatility measured by change_co. It reflects its sensitivity to the results of clinical trials for its innovative technology. This metric is a key component in the formulas on System.GURU.Markets for analyzing the biotech sector.
Daily change in the price of a set of shares in a market segment - Miscellaneous oncology
NovoCure Limited is an oncology company with a unique technology. This chart illustrates the extreme volatility of the sector. Comparing it to NVCR, whose breakthrough tumor field therapy, helps understand its unique risk profile.
Daily change in the price of a broad market stock, index - GURU.Markets
NovoCure is an innovative oncology company that developed tumor treatment field (TTFields) therapy. The biotech sector is extremely volatile, and NovoCure's story is a prime example. The chart below reflects the industry's average price movements, providing context for NovoCure's stock valuation.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization NovoCure Limited
NovoCure developed a revolutionary technology for treating cancer using electrical fields (TTFields). Its year-over-year performance was extremely volatile, reflecting both successes and setbacks in clinical trials of this breakthrough but complex therapy.
Annual dynamics of market capitalization of the market segment - Miscellaneous oncology
NovoCure Limited has developed an innovative technology for treating cancer using electrical fields (Tumor Treating Fields). Its stock price is entirely dependent on the results of clinical trials to expand the application of its unique technology, making it a unique and risky case in oncology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
NovoCure, with its unique cancer treatment technology, is a high-risk, high-potential company. Its stock price is entirely dependent on clinical trial results. The chart isn't about economics, but rather whether investors believe its revolutionary approach will become a new standard in oncology.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization NovoCure Limited
NovoCure, a company that developed a unique method for treating cancer using electrical fields (Tumor Treating Fields). The monthly fluctuations on the graph reflect data from clinical trials using this therapy for new types of cancer.
Monthly dynamics of market capitalization of the market segment - Miscellaneous oncology
NovoCure is an oncology company that has developed an innovative cancer treatment method called Tumor Treating Fields (TTFields), which uses electrical fields to destroy cancer cells. The graph below shows the dynamics of the biotech sector, where breakthrough technologies have the potential to transform approaches to cancer treatment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
NovoCure Limited has developed an innovative cancer treatment called Tumor Treating Fields (TTFields), which uses electrical fields to combat tumors. The company's future depends on clinical success and the acceptance of its technology. The broader market chart serves as just a backdrop to demonstrate how its revolutionary approach to oncology has driven its stock price movement completely independently.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization NovoCure Limited
NovoCure shares reflect weekly hopes for a new method of treating cancer using electrical fields. The company's price movement is highly sensitive to the results of clinical trials, which could expand the application of their unique technology to new types of tumors.
Weekly dynamics of market capitalization of the market segment - Miscellaneous oncology
Innovative cancer treatments are a sector where weekly dynamics depend on clinical data. The search for new approaches, such as electrical field therapy, influences sentiment across the industry. The chart provides this backdrop, which helps us appreciate the uniqueness of NovoCure's technology.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
NovoCure has developed an innovative method of treating cancer using electrical fields (TTFields). Shares of such breakthrough medical companies often move independently of the market. This chart will help you understand: is NovoCure living in its own world of clinical trials and approvals, or is the overall market environment influencing its stock price?
Market capitalization of the company, segment and market as a whole
NVCR - Market capitalization of the company NovoCure Limited
NovoCure's market capitalization chart tells the story of a revolutionary approach to cancer treatment using electrical fields (Tumor Treating Fields). Its volatile dynamics reflect both its success in treating glioblastoma and investors' hopes for the technology's broad application to other cancer types, as confirmed or refuted by clinical trial data.
NVCR - Share of the company's market capitalization NovoCure Limited within the market segment - Miscellaneous oncology
NovoCure is an oncology company with a unique technology for treating cancer using electrical fields (Tumor Treating Fields). Its market share reflects both its commercial success in treating brain tumors and its potential in other areas. This chart tells the story of a breakthrough, yet not yet fully adopted, technology in the fight against cancer.
Market capitalization of the market segment - Miscellaneous oncology
NovoCure is a company that has developed a unique method for treating cancer using electrical fields (Tumor Treating Fields). The chart below shows the market capitalization of the oncology sector. Its dynamics provide the backdrop against which NovoCure is attempting to prove the effectiveness of its unconventional approach and expand its application.
Market capitalization of all companies included in a broad market index - GURU.Markets
NovoCure has developed an innovative method for treating cancer using electrical fields (TTFields). Its high market capitalization is based on the uniqueness of this technology. The chart below shows the potential economic impact of a company that has created a fourth method for fighting cancer, after surgery, chemotherapy, and radiation therapy.
Book value capitalization of the company, segment and market as a whole
NVCR - Book value capitalization of the company NovoCure Limited
NovoCure's book value is derived from its unique electrical field-based cancer treatment device (TTFields) and the capital it has to support extensive clinical trials. This is the tangible, science-intensive capital behind its breakthrough technology. How has this innovative asset evolved? The chart below tells its complex story.
NVCR - Share of the company's book capitalization NovoCure Limited within the market segment - Miscellaneous oncology
NovoCure has developed an innovative method for treating cancer using electrical fields (TTFields), which requires the production of specialized medical devices. The chart shows the share of these unique manufacturing assets, reflecting the physical foundation of its breakthrough oncology technology.
Market segment balance sheet capitalization - Miscellaneous oncology
Medical device development, as the BCap_Seg chart shows, is capital-intensive. NovoCure, in developing its unique TTFields technology for cancer treatment, is investing heavily in R&D and manufacturing infrastructure. Its physical assets are the foundation of its innovative therapies.
Book value of all companies included in the broad market index - GURU.Markets
NovoCure's assets are not drugs, but rather thousands of manufactured electrical field therapy devices and the global infrastructure that supports them. Their book value reflects the physical scale of this unique approach to cancer treatment, based on real, tangible equipment.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - NovoCure Limited
NovoCure has developed an innovative method for treating cancer using electrical fields (Tumor Treating Fields). The company's book value is negligible compared to the potential of its technology. The MvsBCap chart reflects investors' high hopes that this method will be used to treat an increasing number of cancer types, which is being confirmed or refuted by research.
Market to book capitalization ratio in a market segment - Miscellaneous oncology
NovoCure is an oncology company that has developed an innovative method of treating cancer using electrical fields (Tumor Treating Fields). Its valuation is based almost entirely on this unique technology. The chart shows the enormous premium for its scientific breakthrough.
Market to book capitalization ratio for the market as a whole
NovoCure Limited has developed an innovative method for treating cancer using electrical fields (Tumor Treating Fields). Its value lies in this unique, patented technology. The chart illustrates the enormous premium investors are paying for breakthrough approaches in oncology that could change the standard of treatment.
Debts of the company, segment and market as a whole
NVCR - Company debts NovoCure Limited
NovoCure, the company behind the innovative Tumor Treating Fields (TTF) cancer treatment, is utilizing significant capital to conduct extensive clinical trials and global commercialization. This chart shows how the company is funding its breakthrough technology, aiming to make it a standard treatment for various cancer types.
Market segment debts - Miscellaneous oncology
NovoCure Limited has developed an innovative method for treating cancer using electrical fields (Tumor Treating Fields). Commercializing such a breakthrough technology and conducting expensive clinical trials for new indications requires significant capital. This chart illustrates how the company finances its unique medical technology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio NovoCure Limited
NovoCure is developing an innovative tumor-treating field (Tumor Treating Fields) treatment. The chart shows how the company finances its expensive technology. For a company with a revolutionary but not yet widely adopted approach, debt is a sign of investor confidence, but also a significant risk associated with future clinical data and regulatory decisions.
Market segment debt to market segment book capitalization - Miscellaneous oncology
NovoCure is developing an innovative method for treating cancer using electrical fields. This chart for the oncology and biotech sectors shows how much capital is being raised to finance breakthrough but expensive technologies. It helps assess the company's financial risks on its long road to widespread acceptance.
Debt to book value of all companies in the market
NovoCure operates at the forefront of biotechnology. This chart reflects the overall risk appetite in the economy. For a company burning capital for future discoveries, it helps understand how its risky funding model compares to the overall market conditions and investors' willingness to wait.
P/E of the company, segment and market as a whole
P/E - NovoCure Limited
A chart of NovoCure, the developer of innovative electric field-based cancer therapy, shows how investors value its unique technology. The very high values reflect hopes that this treatment will be approved for new tumor types, opening up multi-billion dollar markets for the company.
P/E of the market segment - Miscellaneous oncology
This chart shows the average P/E for the oncology sector, where NovoCure offers a unique technology. The industry's very high average valuation reflects hopes for breakthroughs. This metric provides context for understanding the enormous premium the market places on NovoCure's innovative therapy, even compared to other biotech companies.
P/E of the market as a whole
NovoCure Limited has developed an innovative cancer treatment called Tumor Treatment Fields (TTFields), which uses electrical fields to target cancer cells. This breakthrough technology is groundbreaking. This overall investment climate chart provides insight into the market's belief in the potential of this unique oncology platform to become a new standard of care.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company NovoCure Limited
NovoCure is an oncology company that has developed an innovative method for treating cancer using electrical fields (Tumor Treating Fields). The graph reflects future revenue expectations, which depend on the expansion of this therapy for new types of cancer and increased acceptance by the medical community.
%20P%2FE%20NovoCure%20Limited&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-NovoCure-Limited&v=1772689447162 "Chart of the company's future (projected) P/E NovoCure Limited")
Future (projected) P/E of the market segment - Miscellaneous oncology
NovoCure is an oncology company that has developed an innovative therapy that uses electrical fields to combat cancer cells (Tumor Treating Fields). The chart shows average profitability expectations in the sector, helping to understand the market's confidence in the potential of this unique technology for treating various types of cancer.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Miscellaneous%20oncology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Miscellaneous-oncology&v=1772689447229 "Future (projected) P/E graph of the market segment - Miscellaneous oncology")
Future (projected) P/E of the market as a whole
NovoCure is an oncology company that has developed an innovative cancer treatment method using electrical fields that destroy tumor cells (Tumor Treating Fields). This chart of overall risk appetite in the healthcare sector helps understand the market's readiness to accept and evaluate fundamentally new approaches to oncology treatment.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772689447240 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit NovoCure Limited
NovoCure Limited has developed an innovative cancer treatment called Tumor Treatment Fields (TTFields), which uses electrical fields to target cancer cells. Profits depend on the widespread adoption of this therapy for various types of cancer. This chart shows the financial results of this unique and breakthrough oncology technology.
Profit of companies in the market segment - Miscellaneous oncology
NovoCure Limited has developed an innovative cancer treatment called Tumor Treatment Fields (TTFields), which uses electrical fields to target cancer cells. This graph illustrates the overall profitability of the oncology sector, where breakthrough technologies offering new treatment approaches can create entirely new multibillion-dollar markets.
Overall market profit
NovoCure Limited has developed an innovative method of treating cancer using electrical fields (Tumor Treating Fields). Demand for this therapy is driven by its clinical effectiveness and acceptance by physicians. This business is not dependent on economic cycles, as illustrated by this chart, as the fight against cancer is an absolute priority.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company NovoCure Limited
NovoCure Limited has developed an innovative tumor-treating field therapy (TTF). Future revenue depends on the expansion of this technology to treat various tumor types and insurance reimbursement. This chart reflects analyst expectations for the commercial potential of this unique oncology therapy.
%20profit%20of%20the%20company%20NovoCure%20Limited&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-NovoCure-Limited&v=1772689447317 "Graph of future (projected) profit of the company NovoCure Limited")
Future (predicted) profit of companies in the market segment - Miscellaneous oncology
NovoCure is an oncology company that has developed an innovative cancer treatment called Tumor Treatment Fields (TTFields), which uses electrical fields to target cancer cells. This chart shows revenue projections for the oncology sector, providing context for assessing the potential of this breakthrough technology for treating various types of cancer.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Miscellaneous%20oncology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Miscellaneous-oncology&v=1772689447322 "Graph of future (predicted) profits of companies in a market segment - Miscellaneous oncology")
Future (predicted) profit of the market as a whole
NovoCure Limited has developed an innovative method of treating cancer using electrical fields (Tumor Treating Fields). Its revenue depends on the acceptance of this technology by doctors and patients. This economic outlook affects the overall solvency of the healthcare system, which determines the availability of expensive treatments.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772689447351 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - NovoCure Limited
NovoCure is an oncology company that has developed an innovative method for treating cancer using electrical fields (Tumor Treating Fields). Revenue growth reflects the acceptance of this therapy by doctors and patients. This chart shows the premium investors are paying for this unique technology with potential for application across a wide range of cancer types.
P/S market segment - Miscellaneous oncology
NovoCure is an oncology company that has developed and commercialized an innovative cancer treatment called Tumor Treatment Fields (TTFields), which uses electrical fields to destroy cancer cells. This chart shows the average revenue estimate for the sector, helping to understand how the market values this breakthrough, non-invasive technology.
P/S of the market as a whole
NovoCure Limited has developed an innovative cancer treatment called Tumor Treatment Fields (TTFields), which uses electrical fields to target cancer cells. This chart highlights the enormous premium the market is willing to pay for this breakthrough medical technology, which has the potential to change the paradigm of cancer treatment.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company NovoCure Limited
NovoCure Limited has developed an innovative cancer treatment method called "Tumor Treatment Fields" (TTFields), which uses electrical fields to target cancer cells. Estimating future revenue for such a breakthrough technology is critical. It reflects investor expectations for the expanded use of this method to treat various types of cancer, opening up a huge market.
%20P%2FS%20NovoCure%20Limited&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-NovoCure-Limited&v=1772689447421 "The graph of the company's future (projected) P/S NovoCure Limited")
Future (projected) P/S of the market segment - Miscellaneous oncology
NovoCure is an oncology company that has developed innovative tumor treatment field therapy (TTFields), which uses electrical fields to destroy cancer cells. This chart compares the company's estimated future sales with industry expectations. It shows how investors view current sales and the potential for this technology to treat other types of cancer.
%20P%2FS%20market%20segment%20graph%20-%20Miscellaneous%20oncology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Miscellaneous-oncology&v=1772689447453 "Future (projected) P/S market segment graph - Miscellaneous oncology")
Future (projected) P/S of the market as a whole
NovoCure Limited has developed an innovative method for treating cancer using electrical fields. This unique technology is creating a new market. The revenue growth projections shown in this chart may not necessarily reflect the potential of such breakthrough medical innovations to change treatment standards.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772689447503 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales NovoCure Limited
This figure reflects the revenue of NovoCure Limited, an oncology company that developed the innovative Tumor Treating Fields (TTFields) therapy—the use of electrical fields to combat cancer cells. Revenue is generated from the rental of its Optune medical device. The growth in this figure reflects the expanding use of this unique therapy to treat various types of cancer.
Sales of companies in the market segment - Miscellaneous oncology
NovoCure Limited has developed an innovative cancer treatment called Tumor Treatment Fields (TTFields). Its revenue is generated by leasing its Optune medical device to patients with glioblastoma and mesothelioma. The breakdown of sales by region and indication demonstrates how successfully this new therapy is gaining acceptance.
Overall market sales
NovoCure Limited has developed an innovative method for treating cancer using electrical fields (Tumor Treating Fields). The company's success depends on clinical data and the acceptance of its technology by the medical community. This overall economics is irrelevant for a company offering a fundamentally new approach to oncology, where lives are at stake.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company NovoCure Limited
NovoCure Limited has developed an innovative cancer treatment called Tumor Treatment Fields (TTFields), which uses electrical fields to target cancer cells. Revenue growth depends on the expansion of this therapy across various cancer types. This chart shows analysts' projections for the increase in the number of patients using NovoCure's technology.
%20sales%20of%20the%20company%20NovoCure%20Limited&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-NovoCure-Limited&v=1772689447651 "Schedule of future (projected) sales of the company NovoCure Limited")
Future (projected) sales of companies in the market segment - Miscellaneous oncology
NovoCure Limited has developed an innovative therapy for cancer treatment using electrical fields (Tumor Treating Fields). This chart shows the forecast for the oncology pharmaceutical industry. Is the market expected to grow thanks to the emergence of new, non-invasive treatments? This reflects the overall potential for breakthrough technologies.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Miscellaneous%20oncology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Miscellaneous-oncology&v=1772689447672 "Schedule of future (projected) sales of companies in the market segment - Miscellaneous oncology")
Future (projected) sales of the market as a whole
NovoCure is an oncology company that has developed innovative therapy for treating solid tumors using electrical fields. Demand for its technology is driven by clinical data, physician approval, and insurance coverage. General economic trends, as reflected in this chart, have no impact on patient demand for effective cancer treatment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772689447709 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality NovoCure Limited
NovoCure Limited has developed an innovative cancer treatment called Tumor Treatment Fields (TTFields), which uses electrical fields to target cancer cells. This graph illustrates how profitable this breakthrough oncology technology can be. The company's profitability is directly dependent on the widespread use of its therapy and insurance reimbursement.
Market segment marginality - Miscellaneous oncology
NovoCure Limited has developed an innovative cancer treatment technology called Tumor Treatment Fields (TTFields), which uses electrical fields to target cancer cells. This figure reflects the financial position of the company, which has a unique therapeutic platform, whose profitability depends on the expansion of its technology to treat various types of cancer.
Market marginality as a whole
NovoCure Limited has developed an innovative method for treating cancer using electrical fields (Tumor Treating Fields). Its growth depends on expanding indications for use and the acceptance of the technology by oncologists. This overall profitability chart reflects the state of the economy, which affects the healthcare system's ability to pay for advanced but expensive treatments.
Employees in the company, segment and market as a whole
Number of employees in the company NovoCure Limited
NovoCure develops and markets an innovative device for treating cancer using electrical fields (Tumor Treating Fields). Its staff includes scientists, engineers, and a commercial team. This chart shows how the company is expanding its resources to conduct clinical trials in new areas and to promote its unique therapy globally.
Share of the company's employees NovoCure Limited within the market segment - Miscellaneous oncology
NovoCure is an oncology company that has developed an innovative method for treating cancer using electrical fields (Tumor Treating Fields). Promoting and supporting this therapy requires teams of clinicians, engineers, and patient care specialists. This graph shows the company's market share, reflecting its uniqueness and scale in the medical technology sector.
Number of employees in the market segment - Miscellaneous oncology
NovoCure Limited has developed an innovative cancer treatment method called Tumor Treatment Fields (TTFields), which uses electrical fields to target cancer cells. This chart shows employment in the oncology sector. NovoCure's unique technology represents a new, fourth cancer treatment option, alongside surgery, radiation therapy, and chemotherapy.
Number of employees in the market as a whole
NovoCure is an oncology company that has developed innovative therapies (tumor-targeting fields) that slow the growth of cancer cells. Its growing staff of scientists, engineers, and clinicians reflects the expanding application of this unique technology. Given its overall busy schedule, NovoCure's hiring is a story of fighting cancer with physics, not chemistry.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company NovoCure Limited (NVCR)
NovoCure is an oncology company with a unique technology for treating cancer using electrical fields. This chart shows how the market values their breakthrough therapy. The company's value is embedded in their patents and clinical data. The astronomical market capitalization per employee reflects the monopoly position of their technology.
%20of%20the%20company%20NovoCure%20Limited%20(NVCR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-NovoCure-Limited-NVCR&v=1772689447955 "Chart of market capitalization per employee (in thousands of dollars) of the company NovoCure Limited (NVCR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Miscellaneous oncology
NovoCure (NVCR) is an oncology company that has developed a unique cancer treatment technology (TTFields)—fields that destroy cancer cells. It's a hybrid of medical equipment and therapy. This chart shows the average industry cost per employee. It helps estimate the premium the market pays for their breakthrough (albeit controversial) technology per specialist.
%20by%20market%20segment%20-%20Miscellaneous%20oncology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Miscellaneous-oncology&v=1772689447974 "Market capitalization per employee (in thousands of dollars) by market segment - Miscellaneous oncology")
Market capitalization per employee (in thousands of dollars) for the overall market
NovoCure has developed an innovative method of treating cancer using electrical fields (Tumor Treating Fields). The company's valuation is based on this unique technology. The chart shows a significant valuation per employee, as the market factors in the potential application of this therapy for various tumor types, which is the result of years of research.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772689447993 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company NovoCure Limited (NVCR)
NovoCure is a unique oncology company that treats cancer not with chemotherapy but with "Tumor Treatment Fields" (TTFields)—a specialized wearable device. This chart shows how successfully the company is commercializing this breakthrough technology. It reflects how much revenue the team generates from selling and supporting this expensive treatment.
%20Chart%20NovoCure%20Limited%20(NVCR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-NovoCure-Limited-NVCR&v=1772689447994 "Company Profit Per Employee (in thousands of dollars) Chart NovoCure Limited (NVCR)")
Profit per employee (in thousands of dollars) in the market segment - Miscellaneous oncology
NovoCure (NVCR) is a "medtech" company (their TTFields cancer treatment device). This chart shows the benchmark for "oncology." The average profit per employee in this sector is high. It's an "R&D-driven business." The benchmark reflects the high margins of a patented, "unique" B2B device, which justifies the enormous R&D costs.
%20in%20the%20market%20segment%20-%20Miscellaneous%20oncology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Miscellaneous-oncology&v=1772689448014 "Chart of profit per employee (in thousands of dollars) in the market segment - Miscellaneous oncology")
Profit per employee (in thousands of dollars) for the market as a whole
NovoCure (NVCR) is an oncology company that has developed a unique cancer treatment technology (TTFields)—electric fields that slow cell division. It is a medical device R&D and manufacturing company. This chart shows how much the profit from their current product (for brain tumors) covers the enormous R&D costs for expansion into other cancer types.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772689448020 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee NovoCure Limited (NVCR)
NovoCure is an oncology company that has developed an innovative method for treating cancer using electrical fields (TTFields). This graph demonstrates the commercial success of their unique technology. Their very high revenue per employee reflects the high cost and science-intensive nature of their therapy, which monetizes years of research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-NovoCure-Limited-NVCR&v=1772689448034 "Sales chart per company employee NovoCure Limited (NVCR)")
Sales per employee in the market segment - Miscellaneous oncology
NovoCure (NVCR) has developed an innovative cancer treatment method, Tumor Treatment Fields (TTFields), which uses electrical fields. This unique medical technology is unique. This graph shows the average revenue in the sector. For NVCR, this is an indicator of how productive their unique technology and commercialization team are in generating revenue from this breakthrough treatment.
Sales per employee for the market as a whole
NovoCure is a unique oncology company. They treat cancer not with chemotherapy, but with electrical fields (Tumor Treating Fields) using their device. It's a hybrid of medical technology and therapy. This demonstrates the effectiveness of their revolutionary technology and commercial team.
Short shares by company, segment and market as a whole
Shares shorted by company NovoCure Limited (NVCR)
NovoCure (NVCR) has developed an innovative tumor-treating field (TTF) treatment for glioblastoma. This chart shows the volume of bearish bets. The shorts reflect the market's deep skepticism about whether this technology can prove effective in treating other, more common cancers.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-NovoCure-Limited-NVCR&v=1772689448070 "Short Shares Chart for the Company NovoCure Limited (NVCR)")
Shares shorted by market segment - Miscellaneous oncology
NovoCure (NVCR) is an oncology company that developed the "Tumor Treating Fields" cancer treatment (electric field therapy). This chart aggregates short positions in the oncology sector. It reflects investor skepticism about the widespread adoption of this new method or concerns about clinical trial data.
Shares shorted by the overall market
NovoCure (NVCR) is a cancer treatment device maker (TTFields). This indicator (`Short_All`) is a proxy for market fear. When it rises, investors panic and shed risk. Biotech stocks, even those with approved drugs, often sell off when general pessimism rules the market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator NovoCure Limited (NVCR)
NovoCure is the creator of a unique technology called "Tumor Treatment Fields," a cancer therapy using electrical fields. The company's stock is constantly moving from one clinical trial to another. This chart measures the strength of hope. It shows when optimism about the data (overbought) or fear of failure (oversold) become extreme.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-NovoCure-Limited-NVCR&v=1772689448096 "RSI 14 indicator chart for the company's stock NovoCure Limited (NVCR)")
RSI 14 Market Segment - Miscellaneous oncology
NovoCure is an innovative oncology company behind Tumor Treating Fields (TTFields) technology. This non-invasive treatment (a wearable device) uses electrical fields to target cancer cells. This metric reflects the overall momentum in the oncology equipment sector and helps differentiate the NVCR movement from the broader industry trend.
RSI 14 for the overall market
NovoCure, which develops cancer treatment technology, sees this chart as a reflection of risk appetite in the healthcare sector. During periods of euphoria, investors are willing to fund expensive and time-consuming clinical trials. In times of panic, they flee unprofitable R&D companies, making it difficult for NovoCure to raise capital for new developments.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NVCR (NovoCure Limited)
NovoCure is an oncology company that has developed a fourth cancer treatment option (after surgery, radiation, and chemotherapy)—Tumor Treatment Fields (TTFields). This chart shows the average analyst price target. Their target price is a collective bet on whether clinical trials will prove the effectiveness of TTFields in treating other types of cancer.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NVCR-NovoCure-Limited&v=1772689448307 "A chart showing analyst consensus forecasts for the expected stock price. NVCR (NovoCure Limited)")
The difference between the consensus estimate and the actual stock price NVCR (NovoCure Limited)
NovoCure is an oncology company that has developed a unique technology (Tumor Treating Fields) that uses electrical fields to combat cancer cells (brain tumors). This chart shows the gap between the current market valuation and the analyst target price. It highlights the potential experts see in this non-chemotherapy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NVCR-NovoCure-Limited&v=1772689448358 "A chart showing the difference between the consensus forecast and the actual stock price. NVCR (NovoCure Limited)")
Analyst consensus forecast for stock prices by market segment - Miscellaneous oncology
NovoCure is an oncology company that has developed a revolutionary cancer treatment method—"Tumor Treatment Fields" (TTFields)—using electrical fields. This chart shows general expectations for the oncology sector, reflecting whether experts believe this innovative treatment technology will be widely adopted.
Analysts' consensus forecast for the overall market share price
NovoCure (NVCR) is a company that has developed a fourth cancer treatment. Their Tumor Treating Fields (TTFields) technology is a wearable device that uses electrical fields to slow tumor growth. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough but not yet fully adopted medical technologies.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index NovoCure Limited
NovoCure is a unique oncology company. They treat cancer (especially GBM, or brain cancer) not with chemotherapy but with tumor-treating fields (TTFs)—a specialized wearable device (Optune) that slows cell division. This graph is a barometer of their technology. It likely reflects the growing number of patients using Optune and, more importantly, their R&D progress in applying the fields to other cancer types.
AKIMA Market Segment Index - Miscellaneous oncology
NovoCure (NVCR) is an oncology innovator; the company created the unique TTFields technology, a portable device that uses electrical fields to suppress tumor growth (brain cancer). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this breakthrough (fourth treatment option) model (NVCR) differentiate it from the average pharma company?
The AKIM Index for the overall market
NovoCure is an oncology company that developed Tumor Treating Fields (electric fields for fighting cancer). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this unique medical technology, which is expanding indications, compares to the overall economic trends affecting the sector.
